Navigation Links
Scientists discover ethnic differences in immune response to TB bacterium
Date:7/4/2013

The immune response to the bacterium that causes tuberculosis (TB) varies between patients of different ethnic origin, raising important implications for the development of tests to diagnose and monitor treatment for the disease, according to new research published today in the journal PLOS Pathogens.

The study, led by researchers at Queen Mary, University of London, in collaboration with the Medical Research Council's National Institute for Medical Research (NIMR),analysed the immune response of 128 newly-diagnosed TB patients in London who were divided by ethnicity into those of African (45), European (27), Asian (55) or mixed European/Asian (1) ancestry.

TB is an infection caused by the TB bacterium Mycobacterium tuberculosis. It commonly affects the lungs. While it grew rare in the UK due to BCG vaccination, improvements in living standards and the introduction of effective antibiotic treatment, it has been on the increase since the late 1980s. TB also remains a major global health problem, responsible for nearly nine million new cases and 1.4million deaths in 2011.

By analysing the levels of various inflammatory markers in blood samples taken before treatment, the scientists showed that immune responses of Asians and Europeans were similar to each other, but different from those of Africans. This difference was caused by ethnic variation in the patients' genetic make-up and was not related to the strain of TB bacterium that the patients were infected with.

Dr Adrian Martineau, Reader in Respiratory Infection and Immunity at the Blizard Institute, part of Queen Mary, who led the research, said: "The TB bacterium has co-evolved with humans following migration to Europe and Asia some 70,000 years ago, and different strains of the TB bacterium disproportionately infect particular ethnic groups. Experiments with white blood cells cultured in the lab have shown that different strains of the TB bacterium elicit different amounts of inflammation. One might therefore expect that TB patients' immune responses would differ according to the strain of TB bacterium that they are infected with.

"However our study has shown, for the first time, that it is actually ethnic differences in the patient's genetic make-up that cause most of this variation in immune responses with little effect of the TB strain they are infected with."

By analysing blood samples taken from 85 of the original cohort after an eight-week period of intensive treatment, the researchers found that ethnic variation in immune responses became even more marked. A number of immunological biomarkers, which correlated with either fast or slow clearance of the TB bacteria, were identified and found to differ between Africans and Europeans/Asians.

Dr Anna Coussens, who measured immune responses in patient samples at NIMR, said: "These findings have important implications, both for the development of new diagnostic tests, which increasingly rely on analysing the immune response, and also for work to identify candidate biomarkers to measure response to anti-TB treatment. In the future, diagnostic tests and biomarkers will need to be validated in different ethnic populations."

A key factor in determining the ethnic variation identified in the study appears to be the patients' genetic type of vitamin D binding protein a molecule which binds vitamin D in the circulation.

Dr Martineau said: "There are different genetic types of this protein which vary in frequency between ethnic groups, adding to the growing evidence that vitamin D and the way it is carried in the blood is crucial in determining how a patient's immune system will respond to TB."

Further studies in other populations are now needed to validate the ethnic difference identified.

This work was funded by the British Lung Foundation and the Medical Research Council (MRC).

Dr John Moore-Gillon, Honorary Medical Adviser at the British Lung Foundation, which co-funded the research, said:

"Targeted therapies have long been talked about as the future of medicine. However, in order to develop such treatments, you first need to understand the ways in which the genetic makeup of different people can affect how a disease develops in, and affects, the body. This new research makes great strides forward in doing this for TB, highlighting for the first time how using different approaches for people of differing ethnic backgrounds can help improve our ability to diagnose the disease and monitor the effectiveness of any subsequent treatment.

"TB is a growing problem in the UK. With TB bacteria being notoriously difficult to identify and eradicate from the body, research such as this, that helps improve diagnosis and treatment of the disease, will be vital if we are to keep on top of the battle against its spread."


'/>"/>

Contact: Katrina Coutts
k.coutts@qmul.ac.uk
Queen Mary, University of London
Source:Eurekalert

Related biology news :

1. Scientists identify promising antiviral compounds
2. Harvard and USC scientists show how DHA resolves inflammation
3. Tiny nanocubes help scientists tell left from right
4. Scientists discover thriving colonies of microbes in ocean plastisphere
5. Scientists discover new details about rice blast, a deadly plant fungus
6. Research reveals low exposure of excellent work by female scientists
7. Scientists use DNA from a museum specimen to study rarely observed type of killer whale
8. Hundreds of insect scientists migrating to Rapid City this week
9. Scientists identify potential drug target for treatment-resistant anemias
10. Carnegie Mellon neuroscientists discover new phase of synaptic development
11. OHSU scientists advance understanding of brain receptor; may help fight neurological disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... Calif. (PRWEB) , ... February 24, 2017 , ... Chef ... and wine scene. Making stops in several cities, she gained a number of ... adventure began in Stellenbosch, a town in South Africa’s Western Cape province. It ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
Breaking Biology Technology: